Suraksha Diagnostic Ltd (SURAKSHA) Q4FY26 Management Mirror - Mar-2026 Qtr
Revenue Growth
Management expects an overarching revenue growth rate of 15% YoY for FY27 and beyond, remaining perfectly consistent with expectations established in the Sep'25 Qtr. In the Dec'25 Qtr, the company highlighted that its genomics segment will reach an annual run rate of INR4 crore by FY27 and scale in multiples by FY28, while the Mar'26 Qtr guidance detailed that mature centers will drive 9% of FY27 growth with newly added centers providing the balance. [Status: Reaffirmed]
2 more themes on the ELITE plan.